Last updated: May 24, 2026
Aristada’s supply chain is anchored on (1) the active ingredient (aripiprazole lauroxil) drug substance and (2) the injectable drug product (typically prefilled syringes) that is assembled, filled, and finished for U.S. distribution. Public disclosure is split across FDA listings, commercial supply announcements, and manufacturing-site/IP disclosures. A complete “who supplies what” map depends on the specific dosage form and strength.
Which companies are listed as manufacturers and suppliers for Aristada (aripiprazole lauroxil) on the FDA label?
The primary identifiers used in diligence are the FDA label sections for “Manufactured for” / “Distributed by,” and the prescribing information’s drug product manufacturing section (when present). Those label-based parties are the practical “suppliers” for contracting and distribution planning.
How does FDA labeling identify the Aristada manufacturing chain?
- “Manufactured for” party: entity controlling the finished product in distribution.
- Drug product manufacturer and facility: fill-finish and final release site(s).
- Labeling/distribution party: commercial distributor and U.S. marketing identity.
Aristada dosage forms that drive supplier mapping
Supplier responsibility can change by:
- Strength (eg, 441 mg, 662 mg equivalents, depending on local naming conventions)
- Needle format and syringe configuration
- Packaged presentations (single-dose vs multi-pack)
Who supplies the active ingredient for Aristada: aripiprazole lauroxil drug substance?
Aripiprazole lauroxil is the drug substance. Supplier mapping for the API is typically captured by:
- NDA chemistry/case materials (not broadly indexable)
- Drug master file references (not public in a fully extractable way)
- Public contract manufacturing announcements and manufacturing-site disclosures
What “supplier” means for drug substance
For API procurement, diligence focuses on:
- Drug substance manufacturer
- Salt/form selection (where applicable)
- Particle specs and polymorph control (if relevant)
- Scale-up and technical transfer records
Which CDMOs fill-finish Aristada prefilled syringes in the U.S.?
For injectable long-acting formulations, the fill-finish step is a key operational bottleneck. The practical suppliers for launch continuity are:
- Syringe filling facility
- Sterile finishing and packaging facility
- Quality release testing sites (when separate)
What typically shows up in fill-finish supplier discovery
- Facility name and address in label manufacturing sections
- Batch release testing lab references (sometimes present in regulatory documents)
- Sterility assurance processes for suspended systems
What are the global Aristada manufacturing and supply footprints (NDA vs regional distribution)?
For multinational supply planning, the chain is often:
- API synthesis site(s)
- Drug product manufacturing site(s)
- Regional distribution entities
How regional marketing parties change supplier identification
- U.S. marketing identity can differ from finished product manufacturer and can differ again from distributor.
- Contract logistics and wholesaler networks add apparent “suppliers” that are not manufacturing suppliers.
Which companies are associated with Aristada as commercial manufacturers and distributors?
Aristada is marketed in the U.S. under its established brand identity. In supplier diligence, the “commercial parties” that matter for contracting and regulatory communications are those tied to:
- U.S. label “distributed by” or “manufactured for”
- Change control filings and annual reports (where publicly linked)
- Post-approval manufacturing changes
Supplier contracting implications
- If the label “manufactured for” entity changes, the contract chain changes even when the same physical factory remains.
- Patent and regulatory risk often follows the party controlling the NDA lifecycle.
How do packaging formats (prefilled syringe vs other) affect who supplies Aristada?
Aristada is administered by injection using prefilled syringes. Supplier selection can vary by:
- Syringe and needle components
- Assembly lines
- Elastomer compatibility and seal verification (critical for injectables)
Component sourcing is its own supplier layer
Even when the final fill-finish is stable, sourcing variability may exist for:
- Syringes
- Needles
- Secondary packaging
- Refrigeration/temperature-controlled logistics
What manufacturing-site risks exist for Aristada supply continuity?
Operational risks that drive supplier escalation and dual sourcing planning:
- Sterile manufacturing capacity
- Batch release bottlenecks
- Supply interruptions tied to single-site dependence
- Regulatory constraints on tech transfer
Where risks show up in practice
- FDA changes for manufacturing site revisions
- Recalls or stability failures tied to packaging components
- Contract changes when suppliers consolidate lines
What generic entry risks affect Aristada supply contracts and availability?
Patent and competition dynamics can change procurement strategy:
- If generics/biosimilar-like products are expected to enter, buying leverage increases and manufacturing plans can re-optimize.
- Drug product transition planning (life-cycle management) can shift from high-capex to lower-cost supply chains.
Why this matters for “suppliers” beyond manufacturing
Even if the physical factory stays constant,:
- Contract pricing and minimum order quantities can change
- Forecast-driven production scheduling shifts
What is the fastest way to validate Aristada suppliers for contracting (Orange Book and FDA label method)?
For diligence-grade supplier verification:
- Pull the current prescribing information to identify “Manufactured for” and drug product manufacturing sections.
- Cross-check the FDA database listing for current NDA/RLD and product manufacturing sites.
- Map the chain by dosage strength and presentation to confirm no format-specific swap.
Orange Book usage
- Confirms regulatory identity of the product.
- Helps anchor which NDA/RLD corresponds to which dosage forms.
- Does not, by itself, fully disclose fill-finish or API supplier identity.
Key takeaways
- Aristada supplier mapping must be built from label-based manufacturer/distributor identifiers plus manufacturing-site disclosures.
- The “supplier set” differs by step: API drug substance vs sterile fill-finish vs packaging and distribution.
- For contracting and continuity planning, the actionable parties are those named in the prescribing information for manufacturing/controlled release and the known finished-product release sites.
FAQs
1) Who is the “manufacturer” of Aristada on the U.S. label?
Use the prescribing information sections that name “Manufactured for” and the finished product manufacturing site.
2) Are Aristada prefilled syringes supplied by the same company that supplies the API?
Usually not. API and sterile injectables are commonly separated across different manufacturing networks.
3) Do Aristada suppliers differ by strength or presentation?
They can. Supplier responsibility can change if different strengths use different fill-finish lines or packaging configurations.
4) Where can I find manufacturing-site addresses for Aristada?
The prescribing information “Manufactured by/Manufactured for” and manufacturing section, complemented by FDA product listing data for the specific NDA/RLD and dosage form.
5) How do FDA manufacturing changes affect Aristada supplier continuity?
Site changes typically require regulatory updates. When tech transfer and validation occur, the controlled release and QA release party may shift even if the brand stays the same.
References (APA)
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. (n.d.). Drug product database and labeling for approved products. FDA.
